Tempus AI reports 30.4% YoY revenue growth in FY2024, driven by genomics and data services. Discover key metrics and ...

The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing ...

Tempus signaled its intent to expand beyond cancer when it struck a deal to buy genetic testing company Ambry Genetics for $600 million in November. The company said the takeover would allow it to ...

The financing is intended to support Tempus’ previously announced acquisition of Ambry Genetics ("Ambry"), wh TIFIN AMP Inc. ("TIFIN AMP"), an AI-powered distribution intelligence platform, is excited ...

The financing is intended to support Tempus’ previously announced acquisition of Ambry Genetics ("Ambry"), wh TIFIN AMP Inc. ("TIFIN AMP"), an AI-powered distribution intelligence platform ...

Illumina is teaming up with Tempus AI for a project aimed at promoting the use of DNA sequencing tests across all major areas of disease. The companies said they will work together to train ...

Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S. Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and ...

Illumina Inc. and Tempus AI, Inc., a technology company leading the adoption of AI to advance precision medicine and patient care, announced a collaboration to accelerate clinical adoption of ...

Tempus AI has launched an advisory board of oncology experts to provide guidance and strategic advice to the Chicago-based company on research, product development and clinical use of its AI ...

SAN DIEGO and CHICAGO - Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM) today announced a partnership aimed at advancing the use of artificial intelligence (AI) in genomic ...